Aura Biosciences raises $80m for VDC therapies for cancers
Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies for multiple oncology indications. The funding round of the US-based clinical-stage oncology company was led by Matrix Capital Management and Surveyor Capital, a Citadel company. New investors such as Rock […]